Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Keytruda Extends Top Title Winning Streak to 16th Month in January: Encise
February 7, 2025
- Celltrion Set for 6 Biosimilar Filings in 2 Years, Sees Japanese Data Waiver as a Boon
February 6, 2025
- Izervay Filed for Conditional Approval in Japan: Astellas
February 6, 2025
- FRONTEO/Shionogi Eye FY2026 Approval for AI-Powered Cognitive Test
February 6, 2025
- Sumitomo Pharma CEO Hails Appointment of Parent Firm’s New President
February 5, 2025
- Astellas to Revamp Management in April, Consolidate R&D Functions
February 5, 2025
- Astellas to File Japan NDA for Izervay This Month
February 5, 2025
- Ono Axes ONO-2910 Peripheral Neuropathy Program and More
February 4, 2025
- Mochida President Hails Govt Initiatives to Drive Biosimilar Uptake
February 4, 2025
- Domestic Sites Approved for Meiji’s COVID Vaccine Kostaive
February 4, 2025
- ASKA to Boost Stake in Vietnam’s Ha Tay for Generic Biz Base
February 4, 2025
- Dato-DXd Gets EU Panel Backing for Breast Cancer: Daiichi Sankyo
February 4, 2025
- Daiichi Sankyo, Takeda Restricting Shipments of Mumps Vaccines
February 3, 2025
- Sumitomo Ups FY2024 Earnings Outlook, Now Expects Black Ink
February 3, 2025
- Shionogi to Bolster New Drug Development in China
February 3, 2025
- Daiichi Sankyo Assigns COO Okuzawa as CEO from April
February 3, 2025
- Datroway Now in PIII Study for Adjuvant NSCLC Setting: Daiichi Sankyo
February 3, 2025
- Daiichi Sankyo to Promote COO Okuzawa to CEO
January 31, 2025
- Sarepta Drops DMD Drug Patent Claim against Nippon Shinyaku in Japan
January 31, 2025
- Novo Launches Once-Weekly Insulin Awiqli in Japan
January 31, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…